Hypoxia-directed and activated theranostic agent: Imaging and treatment of solid tumor

Rajesh Kumar, Eun Joong Kim, Jiyou Han, Hyunseung Lee, Weon Sup Shin, Hyun Min Kim, Sankarprasad Bhuniya, Jong Seung Kim, Kwan Soo Hong

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Hypoxia, a distinguished feature of various solid tumors, has been considered as a key marker for tumor progression. Inadequate vasculature and high interstitial pressures result in relatively poor drug delivery to these tumors. Herein, we developed an antitumor theranostic agent, 4, which is activated in hypoxic conditions and can be used for the diagnosis and treatment of solid tumors. Compound 4, bearing biotin, a tumor-targeting unit, and SN38, an anticancer drug, proved to be an effective theranostic agent for solid tumors. SN38 plays a dual role: as an anticancer drug for therapy and as a fluorophore for diagnosis, thus avoids an extra fluorophore and limits cytotoxicity. Compound 4, activated in the hypoxic environment, showed high therapeutic activity in A549 and HeLa cells and spheroids. In vivo imaging of solid tumors confirmed the tumor-specific localization, deep tissue penetration and activation of compound 4, as well as the production of a strong anticancer effect through the inhibition of tumor growth in a xenograft mouse model validating it as a promising strategy for the treatment of solid tumors.

Original languageEnglish
Pages (from-to)119-128
Number of pages10
JournalBiomaterials
Volume104
DOIs
Publication statusPublished - 2016 Oct 1

Fingerprint

Tumors
Imaging techniques
Neoplasms
Therapeutics
Fluorophores
Bearings (structural)
Theranostic Nanomedicine
Hypoxia
Cytotoxicity
Tumor Biomarkers
Biotin
Drug delivery
HeLa Cells
Heterografts
Pharmaceutical Preparations
Antineoplastic Agents
Chemical activation
Tissue
Pressure
Drug Therapy

Keywords

  • Anti-tumor
  • Hypoxia
  • Prodrug
  • Solid tumor
  • Theranostic

ASJC Scopus subject areas

  • Biomaterials
  • Bioengineering
  • Ceramics and Composites
  • Mechanics of Materials
  • Biophysics

Cite this

Kumar, R., Kim, E. J., Han, J., Lee, H., Shin, W. S., Kim, H. M., ... Hong, K. S. (2016). Hypoxia-directed and activated theranostic agent: Imaging and treatment of solid tumor. Biomaterials, 104, 119-128. https://doi.org/10.1016/j.biomaterials.2016.07.010

Hypoxia-directed and activated theranostic agent : Imaging and treatment of solid tumor. / Kumar, Rajesh; Kim, Eun Joong; Han, Jiyou; Lee, Hyunseung; Shin, Weon Sup; Kim, Hyun Min; Bhuniya, Sankarprasad; Kim, Jong Seung; Hong, Kwan Soo.

In: Biomaterials, Vol. 104, 01.10.2016, p. 119-128.

Research output: Contribution to journalArticle

Kumar, R, Kim, EJ, Han, J, Lee, H, Shin, WS, Kim, HM, Bhuniya, S, Kim, JS & Hong, KS 2016, 'Hypoxia-directed and activated theranostic agent: Imaging and treatment of solid tumor', Biomaterials, vol. 104, pp. 119-128. https://doi.org/10.1016/j.biomaterials.2016.07.010
Kumar, Rajesh ; Kim, Eun Joong ; Han, Jiyou ; Lee, Hyunseung ; Shin, Weon Sup ; Kim, Hyun Min ; Bhuniya, Sankarprasad ; Kim, Jong Seung ; Hong, Kwan Soo. / Hypoxia-directed and activated theranostic agent : Imaging and treatment of solid tumor. In: Biomaterials. 2016 ; Vol. 104. pp. 119-128.
@article{e6a77353d21e472ba67f5c2019d9c933,
title = "Hypoxia-directed and activated theranostic agent: Imaging and treatment of solid tumor",
abstract = "Hypoxia, a distinguished feature of various solid tumors, has been considered as a key marker for tumor progression. Inadequate vasculature and high interstitial pressures result in relatively poor drug delivery to these tumors. Herein, we developed an antitumor theranostic agent, 4, which is activated in hypoxic conditions and can be used for the diagnosis and treatment of solid tumors. Compound 4, bearing biotin, a tumor-targeting unit, and SN38, an anticancer drug, proved to be an effective theranostic agent for solid tumors. SN38 plays a dual role: as an anticancer drug for therapy and as a fluorophore for diagnosis, thus avoids an extra fluorophore and limits cytotoxicity. Compound 4, activated in the hypoxic environment, showed high therapeutic activity in A549 and HeLa cells and spheroids. In vivo imaging of solid tumors confirmed the tumor-specific localization, deep tissue penetration and activation of compound 4, as well as the production of a strong anticancer effect through the inhibition of tumor growth in a xenograft mouse model validating it as a promising strategy for the treatment of solid tumors.",
keywords = "Anti-tumor, Hypoxia, Prodrug, Solid tumor, Theranostic",
author = "Rajesh Kumar and Kim, {Eun Joong} and Jiyou Han and Hyunseung Lee and Shin, {Weon Sup} and Kim, {Hyun Min} and Sankarprasad Bhuniya and Kim, {Jong Seung} and Hong, {Kwan Soo}",
year = "2016",
month = "10",
day = "1",
doi = "10.1016/j.biomaterials.2016.07.010",
language = "English",
volume = "104",
pages = "119--128",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Hypoxia-directed and activated theranostic agent

T2 - Imaging and treatment of solid tumor

AU - Kumar, Rajesh

AU - Kim, Eun Joong

AU - Han, Jiyou

AU - Lee, Hyunseung

AU - Shin, Weon Sup

AU - Kim, Hyun Min

AU - Bhuniya, Sankarprasad

AU - Kim, Jong Seung

AU - Hong, Kwan Soo

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Hypoxia, a distinguished feature of various solid tumors, has been considered as a key marker for tumor progression. Inadequate vasculature and high interstitial pressures result in relatively poor drug delivery to these tumors. Herein, we developed an antitumor theranostic agent, 4, which is activated in hypoxic conditions and can be used for the diagnosis and treatment of solid tumors. Compound 4, bearing biotin, a tumor-targeting unit, and SN38, an anticancer drug, proved to be an effective theranostic agent for solid tumors. SN38 plays a dual role: as an anticancer drug for therapy and as a fluorophore for diagnosis, thus avoids an extra fluorophore and limits cytotoxicity. Compound 4, activated in the hypoxic environment, showed high therapeutic activity in A549 and HeLa cells and spheroids. In vivo imaging of solid tumors confirmed the tumor-specific localization, deep tissue penetration and activation of compound 4, as well as the production of a strong anticancer effect through the inhibition of tumor growth in a xenograft mouse model validating it as a promising strategy for the treatment of solid tumors.

AB - Hypoxia, a distinguished feature of various solid tumors, has been considered as a key marker for tumor progression. Inadequate vasculature and high interstitial pressures result in relatively poor drug delivery to these tumors. Herein, we developed an antitumor theranostic agent, 4, which is activated in hypoxic conditions and can be used for the diagnosis and treatment of solid tumors. Compound 4, bearing biotin, a tumor-targeting unit, and SN38, an anticancer drug, proved to be an effective theranostic agent for solid tumors. SN38 plays a dual role: as an anticancer drug for therapy and as a fluorophore for diagnosis, thus avoids an extra fluorophore and limits cytotoxicity. Compound 4, activated in the hypoxic environment, showed high therapeutic activity in A549 and HeLa cells and spheroids. In vivo imaging of solid tumors confirmed the tumor-specific localization, deep tissue penetration and activation of compound 4, as well as the production of a strong anticancer effect through the inhibition of tumor growth in a xenograft mouse model validating it as a promising strategy for the treatment of solid tumors.

KW - Anti-tumor

KW - Hypoxia

KW - Prodrug

KW - Solid tumor

KW - Theranostic

UR - http://www.scopus.com/inward/record.url?scp=84978767500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978767500&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2016.07.010

DO - 10.1016/j.biomaterials.2016.07.010

M3 - Article

C2 - 27449948

AN - SCOPUS:84978767500

VL - 104

SP - 119

EP - 128

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

ER -